Neeuro

Neeuro occupies a specialized position at the intersection of neurotechnology, digital therapeutics, wellness software, and gamified cognitive training. Its differentiation is the combination of a portable EEG device, an AI-enabled interpretation layer, and application software rather than a single-purpose hardware product. SenzeBand 2 captures brain signals alongside PPG and motion data, while NeeuroOS is designed to interpret states such as attention, relaxation, mental workload, and fatigue and to support third-party application development. This gives Neeuro a broader platform proposition than consumer brain-sensing products focused primarily on visualization or meditation. Relative to Neuralink, which is associated with invasive brain-computer interfaces and more ambitious neurological applications, Neeuro emphasizes non-invasive, commercially deployable EEG and health-oriented use cases. Its work with the Institute of Mental Health, Shanghai Dingbo, and Wholeness Co. suggests an emphasis on institutional and regional partnerships, especially in ADHD, cognitive rehabilitation, and preventive brain health. The trade-off is scale and evidence visibility: Neeuro’s disclosed employee range is 11–50, its last recorded financing was a 2018 Series A, and public information does not establish market share or recurring revenue. Its competitive strength is therefore domain integration, while its principal constraints are limited disclosed scale and funding transparency.

Neeuro’s trajectory shows a shift from foundational neurotechnology development toward applied digital therapeutics and international commercialization. The company was founded on Jan 22, 2013, followed by seed financing recorded in 2015 and 2016 and a Series A on May 31, 2018. Although round amounts are unavailable, the three-round history indicates staged capital formation during the platform-building period. The product architecture has since broadened from SenzeBand 2, a portable EEG headband, into NeeuroOS and a portfolio of applications covering attention, memory, stress management, and brainwave visualization. Commercial and partnership milestones became more use-case-specific from 2021 onward. The Shanghai Dingbo collaboration in October 2021 targeted ADHD support in China; the December 2022 Institute of Mental Health programme moved attention training into home-based delivery; and the 2024 Wholeness Co. partnership extended the brain-health proposition into Japan. Hiring for a Chief Operating Officer and China Business Development Director points to operational and market-expansion needs rather than a purely research-led phase. At the same time, the absence of disclosed funding after 2018, quantified revenue or user growth, and recent product-launch records limits confidence in the company’s current expansion rate. The evidence supports gradual platform commercialization, but not a conclusion of rapid scale.